The global phosphatidylinositol 4,5 bisphosphate 3 kinase catalytic subunit beta isoform market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). This gene encodes an isoform of the catalytic subunit of phosphoinositide 3-kinase (PI3K) and is important in signalling pathways that involve receptors on the outer membrane of eukaryotic cells. The major factor driving the market growth include the rising prevalence of cancer across the globe. 

According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US with a mortality rate of 606,520 people in 2020. Additionally, the most common cancers are breast cancer, lung and bronchus cancer, and leukemia, among others. In men, prostate, lung, and colorectal cancers will account for an estimated 43% of all cancers diagnosed while for women, the three most common cancers include breast, lung, and colorectal which will account for an estimated 50% of all new cancer diagnoses in women in 2020. 

Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Hence the rising prevalence of cancer is driving the demand for phosphatidylinositol bisphosphate 3 kinase catalytic subunit beta isoform due to its implicated in the treatment of cancer development and progression which in turn is driving the growth of the market. Phosphatidylinositol-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling is one of the crucial intracellular pathways and therefore, it is regarded as a master regulator for cancer. Some key players in the market include AstraZeneca plc, Bayer AG, and GlaxoSmithKline Plc, among others. 

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- AstraZeneca Plc, Bayer AG, and GlaxoSmithKline Plc, among others. 

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Phosphatidylinositol Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Report by Segment

By Type

• PQR-514

• KA-2237

• GSK-2636771

• BAY-1082439

• Others

By Application

• Cancer

• Myelofibrosis

• Renal Cell Carcinoma

• Other

Global Phosphatidylinositol Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa